RE:Proposed name: COSCIENS Biopharma Inc.They are looking to partner ALS and DC-PTH. If costs for those two programs are the responsibility of future partners as the costs of the diagnostic test clinical trial fall off that could change the forward burnrate. There could also be upfront and milestone payments in the future.
----------
Ensure Go/No-Go decision of amyotrophic lateral sclerosis (“ALS”) project by end of Q1
Objective met: Positive ALS data warrants continuation, a go decision.
----------
Enable evaluation of success probability of ALS vs. delayed clearance parathyroid hormone (“DC-PTH”) project before ASM meeting
Objective met: ALS and DC-PTH seem feasible and we are looking to identify partners for both projects
-------------
MACRILEN partnering in US – Identify a new US and Canadian partner for Macrilen® by the end of 2023.
Objective ongoing.